Business Description
Citius Oncology Inc
NAICS : 325412
SIC : 2834
ISIN : US17331Y1091
Description
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | N/A |
N/A
|
N/A
| |||
| Equity-to-Asset | 0.54 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.24 | |||||
| 9-Day RSI | 37.59 | |||||
| 14-Day RSI | 41.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.37 | |||||
| Quick Ratio | 0.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -41.09 | |||||
| ROA % | -28.08 | |||||
| ROIC % | -31.74 | |||||
| ROCE % | -38.16 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.61 | |||||
| EV-to-EBIT | -5.77 | |||||
| EV-to-Forward-EBIT | -2.98 | |||||
| EV-to-EBITDA | -5.77 | |||||
| EV-to-Forward-Revenue | 2.34 | |||||
| Earnings Yield (Greenblatt) % | -17.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CTOR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Citius Oncology Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.178 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 41.43 | ||
| 14-Day ATR ($) | 0.174267 | ||
| 20-Day SMA ($) | 1.125665 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 0.85 - 4.42 | ||
| Shares Outstanding (Mil) | 71.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Citius Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Citius Oncology Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Citius Oncology Inc Frequently Asked Questions
What is Citius Oncology Inc(CTOR)'s stock price today?
The current price of CTOR is $0.94. The 52 week high of CTOR is $4.42 and 52 week low is $0.85.
When is next earnings date of Citius Oncology Inc(CTOR)?
The next earnings date of Citius Oncology Inc(CTOR) is 2024-12-27 Est..
Does Citius Oncology Inc(CTOR) pay dividends? If so, how much?
Citius Oncology Inc(CTOR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers